Active drug safety surveillance: a tool to improve public health

被引:24
作者
Platt, Richard [1 ,2 ]
Madre, Leanne [3 ]
Reynolds, Robert [4 ,5 ]
Tilson, Hugh [6 ]
机构
[1] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
[3] Duke Translat Med Inst, Durham, NC USA
[4] Pfizer Inc, Dept Epidemiol Safety & Risk Management, New York, NY USA
[5] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA
[6] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA
关键词
drug safety; active surveillance; safety signals;
D O I
10.1002/pds.1668
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Ensuring that drugs have an acceptable safety profile and are used safely is a major public health priority. The Centers for Education and Research on Therapeutics (CERTs) convened experts from academia, government, and industry to assess strategies to increase the speed and predictive value of generating and evaluating safety signals, and to identify next steps to improve the US system for identifying and evaluating potential safety signals. Methods The CERTs convened a think tank comprising representatives of the groups noted above to address these goals. Results Participants observed that, with the increasing availability of electronic health data, opportunities have emerged to more accurately characterize and confirm potential safety issues. The gain for public health from a highly coordinated network of population-based databases for active surveillance is great and within reach, although operational questions remain. A collaborative network must create a working definition of a safety signal, screening algorithms, and criteria and strategies to confirm or refute a signal once identified through screening. Guidelines are needed for when and how to communicate a signal exists and is being evaluated, as well as the outcome of that evaluation. Conclusion A public-private partnership to create a network of government and private databases to routinely evaluate and prioritize safety questions is in the public interest. Better methods are needed, and a knowledgeable workforce is required to conduct the surveillance and understand how to interpret the results. The international community will benefit from the availability of better methods and more experts. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:1175 / 1182
页数:8
相关论文
共 12 条
[1]  
*ANT PREG REG, 2007, WHO WE AR
[2]   Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes - Results from the CRUSADE quality improvement initiative [J].
Bhatt, DL ;
Roe, MT ;
Peterson, ED ;
Li, Y ;
Chen, AY ;
Harrington, RA ;
Greenbaum, AB ;
Berger, PB ;
Cannon, CP ;
Cohen, DJ ;
Gibson, CM ;
Saucedo, JF ;
Kleiman, NS ;
Hochman, JS ;
Boden, WE ;
Brindis, RG ;
Peacock, WF ;
Smith, SC ;
Pollack, CV ;
Gibler, WB ;
Ohman, EM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (17) :2096-2104
[3]  
*CDCP, 2007, EP INT SERV
[4]  
*FOOD DURG ADM, 2008, SENT IN NAT STRAT MO
[5]  
Gliklich R. E., 2007, AHRQ PUBLICATION
[6]  
*I MED, 2007, FOR DRUG DISC DEV TR
[7]  
Institute of Medicine Committee on the Assessment of the US Drug Safety System, 2007, FUT DRUG SAF PROM PR
[8]  
LEWIS E, 2008, MMWR-MORBID MORTAL W, V57, P258
[9]   Real-time vaccine safety surveillance for the early detection of adverse events [J].
Lieu, Tracy A. ;
Kulldorfif, Martin ;
Davis, Robert L. ;
Lewis, Edwin M. ;
Weintraub, Eric ;
Yih, Katherine ;
Yin, Ruihua ;
Brown, Jeffrey S. ;
Platt, Richard .
MEDICAL CARE, 2007, 45 (10) :S89-S95
[10]   Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative [J].
Meine, TJ ;
Roe, MT ;
Chen, AY ;
Patel, MR ;
Washam, JB ;
Ohman, EM ;
Peacock, WF ;
Pollack, CV ;
Gibler, WB ;
Peterson, ED .
AMERICAN HEART JOURNAL, 2005, 149 (06) :1043-1049